PEDIATRICS Vol. 48 No. 5 November 1971, pp. 745-755
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kim, H. W.
Right arrow Articles by Parrott, R. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kim, H. W.
Right arrow Articles by Parrott, R. H.

CLINICAL AND IMMUNOLOGICAL RESPONSE OF INFANTS AND CHILDREN TO ADMINISTRATION OF LOW- TEMPERATURE ADAPTED RESPIRATORY SYNCYTIAL VIRUS

Hyun Wha Kim M.D.1, Julita O. Arrobio M.D.1, Gloria Pyles R.N.1, Carl D. Brandt Ph.D.1, Ena Camargo 1, Robert M. Chanock M.D.1, and Robert H. Parrott M.D.1

1 Research Foundation, Children's Hospital of the District of Columbia; Department of Pediatrics, George Washington University School of Medicine, Washington, D.C.; and the Laboratory of Infectious Disease, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland

Thirty-nine infants and children 6 months to 13 years of age received live 26°C grown respiratory syncytical (RS) virus (strain A2) by the oropharyngeal and nasopharyngeal route. RS virus was recovered from 22 individuals and 17 of these showed a significant rise in CF and/or plaque reduction serum antibody. Twelve of those from whom virus was recovered and an additional three from whom virus was not recovered showed a threefold or greater rise of RS nasal neutralizing activity. Thus 26 of the total showed some evidence of having been infected with the ES strain. The rate of infection was significantly greater in infants and children under 2 years of age than in older children. Infection in individuals older than 8 months of age was asymptomatic. Three infants infected with the vaccine strain had relatively minor respiratory tract illness.

The findings from this study indicate that the low-temperature adapted virus retains a low level of virulence which is expressed only in individuals undergoing primary infection. Nonetheless, these studies have shown that it is possible to induce local and systemic immune responses to RS virus by means other than fully virulent natural infection.

Submitted on February 12, 1971
Accepted on April 28, 1971




This article has been cited by other articles:


Home page
 J. Virol.Home page
P. L. Collins and B. S. Graham
Viral and Host Factors in Human Respiratory Syncytial Virus Pathogenesis
J. Virol., March 1, 2008; 82(5): 2040 - 2055.
[Full Text] [PDF]

Home page
 J. Virol.Home page
M. B. Elliott, K. S. Pryharski, Q. Yu, L. A. Boutilier, N. Campeol, K. Melville, T. S. Laughlin, C. K. Gupta, R. A. Lerch, V. B. Randolph, et al.
Characterization of Recombinant Respiratory Syncytial Viruses with the Region Responsible for Type 2 T-Cell Responses and Pulmonary Eosinophilia Deleted from the Attachment (G) Protein
J. Virol., August 15, 2004; 78(16): 8446 - 8454.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
M. B. Elliott, K. S. Pryharski, Q. Yu, C. L. Parks, T. S. Laughlin, C. K. Gupta, R. A. Lerch, V. B. Randolph, N. A. LaPierre, K. M. H. Dack, et al.
Recombinant Respiratory Syncytial Viruses Lacking the C-Terminal Third of the Attachment (G) Protein Are Immunogenic and Attenuated In Vivo and In Vitro
J. Virol., June 1, 2004; 78(11): 5773 - 5783.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
T. Takimoto, J. L. Hurwitz, C. Coleclough, C. Prouser, S. Krishnamurthy, X. Zhan, K. Boyd, R. A. Scroggs, B. Brown, Y. Nagai, et al.
Recombinant Sendai Virus Expressing the G Glycoprotein of Respiratory Syncytial Virus (RSV) Elicits Immune Protection against RSV
J. Virol., June 1, 2004; 78(11): 6043 - 6047.
[Abstract] [Full Text] [PDF]

Home page
 Br Med BullHome page
W. Olszewska, M. Zambon, and P. J M Openshaw
Development of vaccines against common colds
Br. Med. Bull., July 1, 2002; 62(1): 99 - 111.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
A. C. Schmidt, D. R. Wenzke, J. M. McAuliffe, M. St. Claire, W. R. Elkins, B. R. Murphy, and P. L. Collins
Mucosal Immunization of Rhesus Monkeys against Respiratory Syncytial Virus Subgroups A and B and Human Parainfluenza Virus Type 3 by Using a Live cDNA-Derived Vaccine Based on a Host Range-Attenuated Bovine Parainfluenza Virus Type 3 Vector Backbone
J. Virol., February 1, 2002; 76(3): 1089 - 1099.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
A. C. Schmidt, J. M. McAuliffe, B. R. Murphy, and P. L. Collins
Recombinant Bovine/Human Parainfluenza Virus Type 3 (B/HPIV3) Expressing the Respiratory Syncytial Virus (RSV) G and F Proteins Can Be Used To Achieve Simultaneous Mucosal Immunization against RSV and HPIV3
J. Virol., May 15, 2001; 75(10): 4594 - 4603.
[Abstract] [Full Text]

Home page
 J. Virol.Home page
K. Juhasz, B. R. Murphy, and P. L. Collins
The Major Attenuating Mutations of the Respiratory Syncytial Virus Vaccine Candidate cpts530/1009 Specify Temperature-Sensitive Defects in Transcription and Replication and a Non-Temperature-Sensitive Alteration in mRNA Termination
J. Virol., June 1, 1999; 73(6): 5176 - 5180.
[Abstract] [Full Text]

Home page
 J. Virol.Home page
S. S. Whitehead, C.-Y. Firestone, R. A. Karron, J. E. Crowe Jr., W. R. Elkins, P. L. Collins, and B. R. Murphy
Addition of a Missense Mutation Present in the L Gene of Respiratory Syncytial Virus (RSV) cpts530/1030 to RSV Vaccine Candidate cpts248/404 Increases Its Attenuation and Temperature Sensitivity
J. Virol., February 1, 1999; 73(2): 871 - 877.
[Abstract] [Full Text]

Home page
 J. Virol.Home page
S. S. Whitehead, K. Juhasz, C.-Y. Firestone, P. L. Collins, and B. R. Murphy
Recombinant Respiratory Syncytial Virus (RSV) Bearing a Set of Mutations from Cold-Passaged RSV Is Attenuated in Chimpanzees
J. Virol., May 1, 1998; 72(5): 4467 - 4471.
[Abstract] [Full Text] [PDF]